Navigation Links
USHIFU, LLC Completes Acquisition of Focus Surgery, Inc.
Date:7/2/2008

Combination Creates New Opportunities for Expansion of HIFU Technology

CHARLOTTE, N.C., July 2 /PRNewswire/ -- USHIFU, LLC (USHIFU), the distributor and provider of non-invasive high intensity focused ultrasound for prostate cancer, announced today that it has completed the acquisition of Focus Surgery, Inc. (FSI) of Indianapolis, IN, the creator and manufacturer of the Sonablate(R) 500, an image-guided acoustic ablation device. This acquisition will accelerate USHIFU's ability to expand the FSI HIFU technology platform, as well as gain access to new markets, such as India.

"I speak for the combined USHIFU and Focus Surgery team when I say we are thrilled to announce the acquisition of Focus Surgery. Watching the technological innovation that Focus Surgery scientists and engineers have consistently achieved over the last several years with limited resources has been nothing short of amazing," said Steve Puckett, Jr., CEO USHIFU. "As a much stronger combined entity we are more encouraged than ever about our ability to positively affect healthcare delivery around the world."

"A great milestone in the history of Focus Surgery, Inc. is achieved today as it combines all its technological strength with USHIFU, LLC. The combined Company will make HIFU rapidly available in approved markets worldwide for the treatment of a most deadly disease - cancer, which is very important," said Narendra Sanghvi, President, FSI. "In addition, this is also an extraordinary opportunity to quickly commercialize many of the advanced HIFU applications to create a medical revolution with bloodless surgery while maintaining high quality of life."

About USHIFU, LLC

USHIFU is a healthcare development company and medical device distributor committed to creating a new standard for prostate cancer treatment with high intensity focused ultrasound (HIFU) therapy. USHIFU works with hospitals and medical centers in countries where HIFU is authorized for treating prostate cancer, including Canada, Mexico, the Dominican Republic and the Bahamas, to make the non invasive therapy available. USHIFU is also funding FDA-approved clinical trials in the United States to gather data important for analysis of the technology by the FDA. The first is a pivotal trial for the treatment of primary organ confined prostate cancer that will enroll 466 participants at 24 different centers. A second pivotal trial will begin for the treatment of recurrent prostate cancer in men who have failed external beam radiation therapy. This single arm study will enroll 202 participants at 10 different sites.

About the Sonablate(R) 500

The Sonablate(R) 500 is a non-invasive medical device that utilizes ultrasound energy to destroy tissue within the body. It was developed by FSI and is manufactured by Misonix, Inc. (Nasdaq: MSON) who also holds distribution rights in Europe. Takai Hospital Supply Ltd. and THS International distribute the Sonablate(R) 500 in Southeast Asia and the Middle East.

The Sonablate(R) 500 is not approved for use in the U.S. The Sonablate(R) 500 remains investigational in the U.S. and is being studied for the treatment of prostate cancer in clinical trials in the U.S. FDA has made no decision as to the safety or efficacy of the Sonablate(R) 500 for the treatment of prostate cancer.


'/>"/>
SOURCE USHIFU, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Southern Home Medical Equipment Completes 1-for-1,000 Reverse Split and Begins Trading Under New Symbol SHOM
2. KV Pharmaceutical Company Completes Fiscal 2008 Filings With Securities and Exchange Commission
3. Beeston completes drilling on Bluff Lake property, 100 Mile House
4. PreMD Successfully Completes Project for Health & Beauty Company
5. Sinexus Welcomes New CEO and Completes Series B
6. ACTS Retirement-Life Communities Completes Carlton Cove Acquisition
7. Health Fitness Completes Share Repurchase Plan
8. Lockheed Martin Completes Acquisition of Eagle Group International, LLC
9. The Quantum Group Completes Corporate Expansion Plan; Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 2009
10. Mindray Medical Completes Acquisition of Datascopes Patient Monitoring Business
11. Takeda Completes Acquisition of Millennium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology: